Insilico Medicine

Insilico Medicine

Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions.

The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches under the Geroprotect brand. It also provides a range of consumer-facing applications including Young.AI and Aging.AI and operates Chemistry.AI intended to capture the tacit knowledge and biases of medicinal chemists. The company scientists regularly publish in peer-reviewed journals.

Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual through the Hong-Kong-based Longenesis. The company raised venture capital and partnered with Juvenescence Limited, a rapidly growing biopharmaceutical holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected InsilicoMedicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights.


The most recent information about Insilico Medicine can be found on its website.

Portfolio Companies